Revive Therapeutics Ltd (CVE:RVV) traded up 25% during trading on Tuesday . The company traded as high as C$0.18 and last traded at C$0.18. 226,800 shares changed hands during trading, a decline of 11% from the average session volume of 256,246 shares. The stock had previously closed at C$0.14.
WARNING: “Revive Therapeutics (RVV) Trading 25% Higher” was first published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.wkrb13.com/2018/11/08/revive-therapeutics-rvv-trading-25-higher.html.
Revive Therapeutics Company Profile (CVE:RVV)
Revive Therapeutics Ltd. focuses on the development and commercialization of various drugs in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial.
Featured Article: Benefits of owning preferred stock
Receive News & Ratings for Revive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.